PPT Slide
Alfimeprase Phase 2: Catheter Occlusion
Indication: Catheter occlusion
Design: Multi-center, randomized, double-blind study
Doses: 0.3, 1 and 3 mg of alfimeprase, against the approved dose of Cathflo®Activase® (alteplase)
~100 patients in 20 centers in the U.S.
Lead investigator, Dr. Steven Deitcher of the Cleveland Clinic
Timeline: Dosing commenced June 3, 2003
Endpoints: Safety Restoration of flow Time to lysis